A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase
- PMID: 8650161
- PMCID: PMC39129
- DOI: 10.1073/pnas.93.12.5731
A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase
Abstract
Adenoviral vector-mediated gene transfer offers significant potential for gene therapy of many human diseases. However, progress has been slowed by several limitations. First, the insert capacity of currently available adenoviral vectors is limited to 8 kb of foreign DNA. Second, the expression of viral proteins in infected cells is believed to trigger a cellular immune response that results in inflammation and in only transient expression of the transferred gene. We report the development of a new adenoviral vector that has all viral coding sequences removed. Thus, large inserts are accommodated and expression of all viral proteins is eliminated. The first application of this vector system carries a dual expression cassette comprising 28.2 kb of nonviral DNA that includes the full-length murine dystrophin cDNA under control of a large muscle-specific promoter and a lacZ reporter construct. Using this vector, we demonstrate independent expression of both genes in primary mdx (dystrophin-deficient) muscle cells.
Similar articles
-
In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes.Gene Ther. 1996 Nov;3(11):965-72. Gene Ther. 1996. PMID: 8940636
-
Persistence in muscle of an adenoviral vector that lacks all viral genes.Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1645-50. doi: 10.1073/pnas.94.5.1645. Proc Natl Acad Sci U S A. 1997. PMID: 9050832 Free PMC article.
-
Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells.Hum Mol Genet. 1996 Jul;5(7):913-21. doi: 10.1093/hmg/5.7.913. Hum Mol Genet. 1996. PMID: 8817325
-
[Introduction of rod-deleted dystrophin cDNA, delta DysM3, into mdx skeletal muscle using adenovirus vector].Nihon Rinsho. 1997 Dec;55(12):3148-53. Nihon Rinsho. 1997. PMID: 9436426 Review. Japanese.
-
Progress toward gene therapy of Duchenne muscular dystrophy.Semin Neurol. 1999;19(3):323-32. doi: 10.1055/s-2008-1040848. Semin Neurol. 1999. PMID: 12194388 Review.
Cited by
-
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.Heliyon. 2024 Jul 20;10(15):e34927. doi: 10.1016/j.heliyon.2024.e34927. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39144987 Free PMC article. Review.
-
Therapeutic strategies for the inherited neuropathies.Neuromolecular Med. 2006;8(1-2):255-78. doi: 10.1385/nmm:8:1-2:255. Neuromolecular Med. 2006. PMID: 16775380
-
Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.J Virol. 1999 Dec;73(12):10426-39. doi: 10.1128/JVI.73.12.10426-10439.1999. J Virol. 1999. PMID: 10559361 Free PMC article.
-
Conditionally replicating adenoviruses for cancer treatment.Curr Cancer Drug Targets. 2007 May;7(3):285-301. doi: 10.2174/156800907780618301. Curr Cancer Drug Targets. 2007. PMID: 17504125 Free PMC article. Review.
-
The companions: regulatory T cells and gene therapy.Immunology. 2009 May;127(1):1-7. doi: 10.1111/j.1365-2567.2009.03069.x. Immunology. 2009. PMID: 19368560 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources